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Abstract
Vestibular schwannomas (VS) are slow-growing intracranial extraaxial benign tumors, developing from the vestibular part of 
the eight cranial nerves. Stereotactic radiosurgery (SRS) has now a long-term scientific track record as first intention treatment 
for small- to medium-sized VS. Though its success rate is very high, SRS for VS might fail to control tumor growth in some 
cases. However, the literature on repeat SRS after previously failed SRS remains scarce and reported in a low number of 
series with a limited number of cases. Here, we aimed at performing a systematic review and meta-analysis of the literature 
on repeat SRS for VS. Using PRISMA guidelines, we reviewed manuscripts published between January 1990 and October 
2020 and referenced in PubMed. Tumor control and cranial nerve outcomes were evaluated with separate meta-analyses. 
Eight studies comprising 194 patients were included. The overall rate of patients treated in repeat SRS series as per overall 
series with first SRS was 2.2% (range 1.2–3.2%, p < 0.001). The mean time between first and second SRS was 50.7 months 
(median 51, range 44–64). The median marginal dose prescribed at first SRS was 12 Gy (range 8–24) and at second SRS 
was 12 Gy (range 9.8–19). After repeat SRS, tumor stability was reported in 61/194 patients, i.e., a rate of 29.6% (range 
20.2–39%,  I2 = 49.1%, p < 0.001). Tumor decrease was reported in 83/194 patients, i.e., a rate of 54.4% (range 33.7–75.1%, 
 I2 = 89.1%, p < 0.001). Tumor progression was reported in 50/188 patients, i.e., a rate of 16.1% (range 2.5–29.7%,  I2 = 87.1%, 
p = 0.02), rarely managed surgically. New trigeminal numbness was reported in 27/170 patients, i.e., a rate of 9.9% (range 
1.4–18.3%, p < 0.02). New facial nerve palsy of worsened of previous was reported in 8/183 patients, i.e., a rate of 4.3% 
(range 1.4–7.2%, p = 0.004). Hearing loss was reported in 12/22 patients, i.e., a rate of 54.3% (range 24.8–83.8%,  I2 = 70.7%, 
p < 0.001). Repeat SRS after previously failed SRS for VS is associated with high tumor control rates. Cranial nerve out-
comes remain favorable, particularly for facial nerve. The rate of hearing loss appears similar to the one related to first SRS.
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Introduction
Vestibular schwannomas (VS) are intracranial extraaxial 
benign tumors, slow growing, developing from the vestibu-
lar part of the eight cranial nerves [47]. They account for 
approximately 10% of primary brain tumors [57]. The rela-
tive incidence is 0.6–0.8 per 100,000 individuals per year 
[47]. Due to the increased use of advanced radiographic 
imaging, and in particular contrast-enhanced magnetic 
resonance imaging (MRI), more and more VS are diag-
nosed incidentally in patients without any symptom. The 
most common symptom is unilateral hearing decline, fol-
lowed by tinnitus and vertigo [19]. Classically, VS are fre-
quently diagnosed around the fifth decade of life. Most of 
the authors report female preponderance [39]. It has been 
recently acknowledged that three different growth patterns 
are commonly described, including no/very slow growth, 
slow growth (2 mm/year), or fast growth (> 8 mm/year) 
[21]. Such variety of tumor growth rates and interventional 
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outcomes, including for incidentally discovered lesions, 
make long-term management a matter of debate [46].
The current gold standard for diagnosis is thin-cut axial 
MRI of the head with contrast enhancement (gadolinium) 
[4]. Recent evidence suggested that non-enhanced thin-slice 
T2-weighted MRI might be sufficient for initial screening 
[5]. The advantages of such approach include not only 
reduced risk of adverse reactions, but also reduced cost [4]. 
Moreover, this offers also a high contrast between the VS, 
cerebrospinal fluid, and the adjacent structures [36]. The 
T2 CISS is also considered highly sensitive and specific in 
detecting small VS, close to the T1 gadolinium weighted. 
The MRI allows evaluating volumetric course during time. 
Various measurements have been applied, including mm/
year-based model,  cm3/year-based model, and a volume-
doubling time (VDT)-based model. Some authors suggested 
that VDT-based model was the most accurate in describing 
VS growth [56].
Newly diagnosed VS can benefit from “wait and scan” 
strategy [21], stereotactic radiosurgery (SRS) [28, 43, 52], 
radiotherapy [51], or microsurgical resection [6, 48, 55]. 
Recurrent or progressive residual VS might be treated by 
SRS [15] or microsurgical resection [38] depending on 
tumor volume and patients’ specific characteristics (age, 
medical comorbidities) [49]. In the opinion of some authors, 
microsurgery remains the most prevalent strategy, which is 
particularly applicable to large VS. However, during the 
recent years, there has been an increasing trend towards 
“wait-and-scan” [22] and SRS, the former especially for 
small- to medium-sized tumors, or in the frame of combined 
approaches, following planned subtotal resection [6, 16].
Stereotactic radiosurgery is beginning to have a long-
term scientific track record as first intention treatment for 
small- to medium-sized VS, with high tumor control rates 
and low morbidity rates. In case of failure, which can occa-
sionally occur, microsurgical resection is generally advo-
cated. Recently, there is a growing literature with regard to 
the role of repeat SRS for growing VS after the first failed 
SRS treatment [11, 15]. Thus, some authors advocated for 
the use of a second SRS instead of microsurgical resection, 
whenever possible, alone or in combination with the former, 
in the frame of combined approaches [55]. However, the 
total number of patients reported is quite low, and the exact 
safety and efficacy are not widely accepted. Moreover, the 
exact indications might vary among centers. Thus, the lit-
erature on this topic is scarce.
Here, we performed systematic review and meta-analysis of 
series reporting retreatment by SRS for growing VS after pre-
viously failed SRS. We have chosen this topic as, up-to-date, 
the literature is scarce and includes a limited number of series. 
Moreover, the number of patients included in the reported 
series is low. There are several pending questions related to 
the role of retreatment by SRS (after first SRS) of VS including 
the timing of second SRS, the tumor control, and the potential 
induced neuropathies (including hearing preservation) as well 
as how to manage radiation-induced changes, related both to 
tumor swelling with further pseudoprogression appearance. 
Thus, we describe tumor control rates, as well as cranial nerve 
outcomes (whenever reported), with complications and their 
relative incidence. We present the indications for such retreat-
ment, as depicted in the current literature.
Methods
Article selection and data extraction
A PubMed search was performed for entries between January 
1990 and October 2020 using the following query guidelines: 
((vestibular AND (radiosurgery OR Gamma Knife)) AND 
(schwannoma) OR (retreatment)). Inclusion criteria were as fol-
lows: peer-reviewed clinical study or case series of VS retreated 
with SRS, independently of the device, clearly specified and pre-
sented as independent series of second SRS. Excluded were as 
follows: abstract, case reports, non-English studies, conference 
papers and series where fractionated radiotherapy was used.
Eight studies comprising 194 patients were included [7, 
9, 11, 15, 18, 26, 27, 61]. The detailed study characteristics 
can be seen in Tables 1, 2, and 3. There were only Gamma 
Knife (GK, Elekta Instruments, AB, Sweden) studies includ-
ing reports of second SRS after a first failed SRS. No Lin-
ear Accelerator (Linac) or Cyberknife studies specifically 
reported outcomes following retreatment, in the frame of a 
separate clinical article.
The article selection is collated in Fig. 1. Two separate 
reviewers (AB, CT) applied the inclusion criteria to the Pub-
Med search result; there were no disagreements.
This study was performed in accordance with the pub-
lished Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines [33].
Data extraction was performed as per individual study, 
while paying special attention to tumor control aspects (stabil-
ity, decrease, increase) and cranial nerve outcomes (pertaining 
to trigeminal, facial, and/or cochlear and vestibular nerves).
Indication for retreatment
Treatment failure has been heterogeneously defined among 
studies, usually as continuous growth requiring subsequent 
intervention after a minimum 2 years of follow-up [61]. 
Some authors classified the response to GK as regression 
(more than 10% volume reduction), stabilization (volume 
variation within 10%), enlargement (more than 10% vol-
ume increase not requiring further intervention), and failure 
(uncontrollable tumor growth requiring further intervention 




The House-Brackmann scale was used to asses facial nerve 
function [14]. The Gardner-Robertson scale was used to 
assess hearing function, defined as functional hearing for 
classes I and II [10].
Adverse radiation events
Magnetic resonance imaging (MRI) was used to assess pres-
ence of edema at cerebellar and/or brainstem level. The most 
frequently used sequences were T2 w (CISS) and FLAIR.
Statistical analysis using OpenMeta (Analyst) 
and random‑effects model
Due to the high variation in study characteristics, a statistical 
analysis using a binary random-effects model (DerSimonian-
Laird method) was performed. We used OpenMeta (analyst) 
software from the Agency for Healthcare Research and Quality.
Weighted summary rates were determined using meta-
analytical models. Testing for heterogeneity was performed 
for each meta-analysis.
Pooled estimates using meta-analytical techniques were obtained 
for all the outcomes previously described in the same section.
Results
Number of patients in repeat SRS series 
as per overall series with first SRS
The overall rate of patients treated in repeat SRS series as 
per overall series with first SRS was 2.2% (range 1.2–3.2%, 
 I2 = 92.5%, p heterogeneity < 0.001, p < 0.001) (Fig. 2).
Time between first and second SRS
The mean time between first and second SRS was 
50.7  months (median 51, range 44–64). The minimal 
and maximal time frames were 12 and 185  months, 
respectively.
Marginal dose prescription
The median marginal dose prescribed at first and second SRS 
were 12 Gy (range 8–24) and 12 Gy (range 9.8–19), respectively.
Tumor control after repeat SRS
Tumor stability after retreatment was reported in 61/194 
patients, i.e., a rate of 29.6% (range 20.2–39%,  I2 = 49.1%, 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tumor decrease after retreatment was reported in 
83/194 patients, i.e., a rate of 54.4% (range 33.7–75.1%, 
 I2 = 89.1%, p heterogeneity p < 0.001, p < 0.001; Fig. 3b).
Tumor progression after retreatment was reported in 
50/188 patients, i.e., a rate of 16.1% (range 2.5–29.7%, 
 I2 = 87.1%, p heterogeneity p < 0.001, p = 0.02; Fig. 3c).
Transient tumor expansion after SRS
Transient tumor expansion after SRS was specifically 
reported in two series [15, 27], ranging between 17.5 and 
42.8%.
Cranial nerve outcomes after repeat SRS
New trigeminal numbness after retreatment was reported 
in 27/170 patients, i.e., a rate of 9.9% (range 1.4–18.3%, 
 I2 = 76.36%, p heterogeneity p < 0.001, p = 0.02; Fig. 4a).
New facial nerve palsy of worsened facial nerve outcome 
of previously existing one was reported in 8/183 patients, 
i.e., a rate of 4.3% (range 1.4–7.2%,  I2 = 0%, p heterogeneity 
p = 0.905, p = 0.004; Fig. 4b).
Hearing loss after retreatment was reported in 12/22 
patients, i.e., a rate of 54.3% (range 24.8–83.8%,  I2 = 70.7%, 
p heterogeneity p = 0.002, p < 0.001; Fig. 4c).
Ventriculo‑peritoneal shunt
One series [26] reported the necessity of a ventriculo-
peritoneal shunt 22 months after second SRS in one case.
Discussion
The results of our systematic review and meta-analysis show 
that repeat SRS for VS remains safe and effective, as the 
results after a first SRS [17]. Here, we included 8 studies 
comprising 194 patients, all treated with GK as second SRS 
after a previously failed SRS for VS. We report overall tumor 
stability in 29.6% of cases, decrease in 54.4%, and further 
tumor progression in 16.1%. However, only a small number 
of cases with further progression underwent surgical resec-
tion in the reported series. This is most probably related 
to pseudoprogression phenomenon, although this was not 
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clearly stated. Moreover, such pseudoprogression appeared 
to be as high as 42% in one of the included studies. The rate 
of new trigeminal neuropathy was 9.9%. The rate of facial 
nerve palsy appearance or worsening was 4.3%. Of note, 
after first SRS, trigeminal preservation rates vary between 
74 and 99% [8, 12, 21, 24, 31, 41, 44, 55] and facial pres-
ervation ranges between 84 and 100% [8, 12, 21, 24, 31, 
41, 44, 55]. In a recent meta-analysis (which included 45 
articles and 4234 patients), the crude rate of hearing preser-
vation after first SRS was 51% at a median follow-up period 
of 44 + / − 32 months [60]. In the present meta-analysis, the 
rate of hearing loss was 54.3% going up to as high as 83.8%. 
The rate of hearing loss after second SRS appears similar to 
the one after first SRS.
Fig. 1  Prisma flowchart with 
study selection details
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Fig. 2  Number of patients in 
repeat SRS series as per overall 
series with first SRS
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The largest series included in the present meta-analysis 
was the one of Iorio-Morin et al. [15] which analyzed 76 
patients. The authors reported high actuarial tumor control 
rates at 2, 5, and 10 years following SRS of 98.6%, 92.2%, 
and 92.2%, respectively. Worsening of the facial nerve func-
tion attained 7%. In another series, Fu et al. [9] reported 
100% tumor control after second SRS after a median follow-
up period of 75 months. Volumetric tumor response after the 
second procedure could not be predicted by the volumetric 
response after first SRS. Thus, the authors concluded that 
this justifies considering repeat SRS even for tumors that did 
not show any volumetric response and displayed continuous 
growth after first treatment. Moreover, there is an increased 
risk of mild facial and trigeminal nerve dysfunction after 
second as compared to first SRS. Such results fairly com-
pared to what is reported here in our meta-analysis.
The timing for retreatment after first SRS failure 
for VS has been controversial in the current literature. 
Retreatment indication for microsurgery or SRS is usu-
ally related to tumor (volume, edema) or patient (age, 
symptoms, medical comorbidities) specific factors. With 
regard to tumor-related aspects, one should keep also in 
mind the probability of transient tumor expansion (TTE) 
[42], which varies between 17 and 74% of patients after 
first GK [13, 35, 62]. Classically, TTE typically occurs 
between 3 and 9 months after first GK treatment, with a 
peak at 6 months, induced by internal swelling [34]. This 
should not be confounded with real tumor progression. 
Fig. 3  Tumor control rates 
after SRS for VS: a stability; b 
tumor; c progression rates
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Subsequent volumetric measurement is the key to evalu-
ate such progression, while some authors suggested even 
preradiosurgical radiomics [59]. One should keep in mind 
that at least 2 years follow-up is usually required [23], 
avoiding misjudging any temporary tumoral swelling [32]. 
This should be further judged in the context of presence 
or absence of patient’s symptoms. Additional neuroimag-
ing assessment (other than MRI) might be also useful. In 
a series by Lonneville et al. [27], the authors evaluated 
the role of PET during follow-up course, which showed a 
significant metabolic decrease of the tumor, further con-
sidered as TTE. Moreover, one other particular aspect 
is related to potential cystic components or entrapment 
cysts [29], the latter with much-complicated decision 
making, depending on the clinical context [53]. With 
regard to patient-related aspects, indications for additional 
management after initial GK might include trigeminal neu-
ropathy (numbness, trigeminal pain, facial neuropathy), 
facial neuropathy (palsy, hemifacial spasm [18]), or ves-
tibular (major imbalance).
In line with the previous, the definition of treatment fail-
ure after first SRS is not always straightforward. In our opin-
ion, several key aspects should be considered before con-
cluding treatment failure: duration of at least 2 years after 
first SRS (preferably even 3–4 years, unless symptomatic 
mass effect) and minimum 3 time points of follow-up MRI 
displaying continuous growth. Further decision to retreat 
should be delayed in absence of symptomatic mass effect. 
Transient tumor expansion should always be kept in mind, 
and is frequently associated with transient loss of central 
contrast enhancement. Clinically relevant tumor progression 
should be certainly differentiated from TTE and should rule 
Fig. 4  Specific cranial nerve 
outcomes after SRS: a trigemi-
nal; b facial; c cochlear
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the therapeutic decision. The neurosurgical team involved 
in decision making should be aware of classical changes 
after SRS.
Following primary SRS, 5-year tumor control rate is 
90–98% [1, 3, 28]. The key factor in retreating VSs with 
SRS is to formally consider that first SRS was a failure. In 
some series [11], the indication for retreatment was small- to 
medium-sized VS, less than 30 mm in diameter with doc-
umented tumor growth. While a vast majority of authors 
agree to irradiation of the whole VS during second SRS, 
some series advocated to irradiate only the progressive part 
of the tumor [27]. In our opinion, such an approach is not 
taking into account the radiobiological aspects [54], which 
might not consider several aspects pertinent to the tumor 
itself. Patients with a VS needing repeat treatment after ini-
tial SRS are a selected group of patients, with somehow 
unfavorable tumor response due to SRS and, most probably, 
a different radiobiological response. Another strategy, pre-
sented in the same study, was to perform even third irradia-
tion for tumor growth [27]. However, such strategy might 
engender further TTE and additional symptoms. Advantages 
of SRS as preferred treatment modality in this indication are 
also related to avoid risks of open microsurgical resection, 
including meningitis (1–3%) [45], hydrocephalus [40], or 
cerebro-spinal fluid leakage [2].
A key factor for tumor control is the marginal dose to be 
prescribed. Both in the literature and in our experience, we 
do not favor prescribing marginal doses of less than 11 Gy 
at the time of first or second GK. As illustrated here, some 
of the patients received even doses of less than 10 Gy, which 
might explain failures of first and/or second SRS [20]
Here, we reported rates up to 10% of trigeminal nerve 
neuropathy. Such results should take into account the related 
volume of VS (close to the trigeminal nerve or in contact 
with the former). Also, dosimetric aspects are highly impor-
tant, such as the location of the trigeminal root entry zone 
(REZ) in relationship with parts of the VS, REZ which 
should be visualized and excluded from the prescription 
isodose line, if possible. Another aspect is related to the 
interface with the brainstem, which should receive the steep-
est gradient during treatment planning [37]. Facial nerve neu-
ropathy remains rare after repeat SRS, with an overall rate 
of 4.2%, similar to that of first SRS. Hearing preservation is 
probably the most challenging aspect after second GK. The 
dose to the cochlea has been now standardly reported for first 
SRS [30, 50], but scarcely after the second one.
The effects of radiosurgery on the cochlear nerve in the 
literature have been frequently attributed to user technique. 
It has been previously acknowledged that the maximal 
dose received by the cochlea after a first SRS might play 
a role in hearing decline during follow-up course [50]. 
The data of cumulative cochlear dose (at first and second 
SRS, respectively) remain scarce and are frequently not 
reported. An additional aspect is that most users measure 
such dose only at the level of the modulus itself. Linskey 
et al. [25] suggested that the basal turn of the cochlea 
should also receive the lowest possible dose (ideally less 
than 4–5.3 Gy). Moreover, other authors advocated for a 
role of radiation dose rate, especially in the appearance 
of clinical acute and subacute effects after first SRS [52].
No patient developed radiation-induced tumors [58].
Future directions of clinical research shall include fre-
quency of pseudoprogression phenomenon with the exact 
timing, MRI aspect, more clear definition of failure (clinical 
and/or radiological), and strong reliable markers of failure, 
including on neuroimaging.
Our meta-analysis has several inherent limitations. One 
limitation is related to patients, which previously received 
also another type of radiation. In this sense, only one 
patient included in a study [7] was previously treated with 
proton beam therapy (inside a series of 11 patients). How-
ever, in that series, the specific outcomes were not detailed 
as per patient. A second limitation is related to the mini-
mal tumor coverage at the time of first SRS which varies 
depending on studies, as some authors reported a minimal 
cutoff of 90% [9]. This could have further influenced tumor 
control. A third limitation might be related to previously 
used treatment paradigms. Some series included, beside 
repeat GK after initial GK, a second GK after initial com-
bined approach (subtotal microsurgical resection followed 
by SRS) [9]. Such tumors benefiting from previous micro-
surgical resection might have had a different radiobiology, 
although such aspect remains purely theoretical.
Conclusion
Repeat SRS after previously failed SRS for VS is associ-
ated with high tumor control rates. Tumor progression was 
reported in an overall rate of 16%, while only some series 
reported further necessity of surgical management. Thus, in 
case of such progression, one should exclude a TTE. Cranial 
nerve outcomes remain favorable, particularly concerning 
the facial nerve. Hearing loss rates are similar to first SRS.
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